Association of increased oncostatin M with adverse left ventricular remodeling in patients with myocardial infarction
OSM and post-infarction left ventricular remodeling
Abstract
Background: The study of laboratory biomarkers that reflect the development of adverse cardiovascular events in the postinfarction period is of current relevance. The aim of the present study was evaluation of oncostatin M (OSM) concentration changes in the early and late stages of myocardial infarction and evaluation of the possibility of its use in prediction of adverse left ventricular remodeling in patients with myocardial infarction with ST-elevated segment (STEMI).
Methods: The study involved 31 patients with STEMI admitted in the first 24 hours after the onset of MI and 30 patients with chronic coronary artery disease as a control group. Echocardiographic study was performed on day 3 and in 6 months after STEMI. The serum levels of biomarkers were evaluated on the day of hospital admission and 6 months after MI using multiplex immunoassay.
Results: OSM level increased during the first 24 h after the onset of the disease, with the following decrease in 6 months. OSM concentration at admission had correlated with echocardiography parameters and Nt-porBNP, troponin I, CK-MB levels. Our study has demonstrated association of the increased levels of OSM at the early stages of STEMI with development of the adverse LV remodeling in 6 months after the event.
Conclusion: Elevation of OSM levels in the first 24 h after STEMI is associated with the development of the adverse LV remodeling in the long-term post-infarction period.
References
2. Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord. 2017;17:53. doi: 10.1186/s12872-017-0482-9
3. Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. J Am Coll Cardiol HF. 2018;6:179-186. doi: 10.1016/j.jchf.2017.09.015
4. Mareev VY, Ageev FT, Arutyunov GP, et al. National recommendations of OSSN, RKO and RNMOT on diagnosis and treatment of CHF (fourth revision) // Journal of Heart Failure. 2013;7:0379-472.
5. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322. doi: 10.1161/cir.0000000000000152.
6. Li J, Dharmarajan K, Bai X, et al. Thirty-day hospital readmission after acute myocardial infarction in China. Circ Cardiovasc Qual Outcomes. 2019;12(5):e005628. doi:10.1161/CIRCOUTCOMES.119.005628
7. Anzai T. Inflammatory mechanisms of cardiovascular remodeling. Circ J. 2018;82(3):629-635. doi: 10.1253/circj.CJ-18-0063
8. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction. Circ Res. 2016;119:91-112. doi: 10.1161/CIRCRESAHA.116.303577
9. Konstantinova EV, Konstantinova NA. Cellular and molecular mechanisms of inflammation in pathogenesis of myocardial infarction (Literature review). Vestnik RGMU. 2010;1:60–64.
10. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773–789. doi: 10.1038/s41577-018-0066-7
11. Sazonova SI, Ilushenkova JN, Batalov RE, et al. Plasma markers of myocardial inflammation at isolated atrial fibrillation. J Arrhythm. 2018;34(5):493-500. doi:10.1002/joa3.12083
12. Hohensinner PJ, Kaun С, Rychli K, et al. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J. 2009;23(3):774–782. doi: 10.1096/fj.08-108035
13. Zhang X, Li J, Qin J-J, et al. Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages. J Lipid Res. 2017;58:895–906. doi:10.1194/jlr.M074112
14. Stawski L, Trojanowska M. Oncostatin M and its role in fibrosis. Connect Tissue Res. 2019; 60(1):40–49. doi:10.1080/03008207.2018.1500558
15. Kubin T, Pöling J, Kostin S, et al. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell. 2011;9(5):420–432. doi: 10.1016/j.stem.2011.08.013.
16. Richards CD, Botelho F. OncostatinM in the regulation of connective tissue cells and macrophages in pulmonary disease. Biomedicines. 2019;7(4):95. doi: 103390/biomedicines7040095.
17. Hu J, Zhang L, Zhao Z, et al. OSM mitigates post-infarction cardiac remodeling and dysfunction by up-regulating autophagy through Mst1 suppression. Biochim. Biophys. Acta Mol Basis Dis. 2017;1863(8):1951–1961. doi:10.1016/j.bbadis.2016.11.004
18. Kovalyova ON, Kochubei ОA. Oncostatin M is a proinflammatory cytokines and its role in the cardiovascular disease. Scientific statements BelSU. Series: Medicine. 2014;11(182):5–8.
19. Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26(5):545–558. doi: 10.1016/j.cytogfr.2015.07.006
20. West NR, Owens BMJ, Hegazy AN. The oncostatin M-stromal cell axis in health and disease. Scand J Immunol. 2018;88(3):e12694. doi: 10.1111/sji.12694
21. Szibor M, Pöling J, Warnecke H, et al. Remodeling and dedifferentiation of adult cardiomyocytes during disease and regeneration. Cell. Mol. Life Sci. 2014;71(10):1907–1916. doi: 10.1007/s00018-013-1535-6
22. Ikeda S, Sato K, Takeda M, et al. Oncostatin M is a novel biomarker for coronary artery disease - A possibility as a screening tool of silent myocardial ischemia for diabetes mellitus. Int J Cardiol Heart Vasc. 2021;35:100829. doi: 10.1016/j.ijcha.2021.100829
23. Gruson D, Ferracin B, Ahn SA, Rousseau MF. Elevation of plasma oncostatin M in heart failure. Future Cardiol. 2017;13(3):219-227. doi: 10.2217/fca-2016-0063
24. Galli A, Lombardi,F. Postinfarct Left Ventricular Remodelling: A prevailing cause of heart failure. Cardiology Research and Practice. 2016;2016:2579832. doi: 10.1155/2016/2579832
25. Zhang X, Zhu D, Wei L, et al. OSM enhances angiogenesis and improves cardiac function after myocardial infarction. Biomed Res Int. 2015;2015:317905. doi: 10.1155/2015/317905
26. Li X, Zhang X, Wei L, et al. Relationship between serum oncostatin M levels and degree of coronary stenosis in patients with coronary artery disease. Clinical Laboratory. 2014;60(1):113–118. doi: 10.7754/clin.lab.2013.121245
27. Ashcheulova T, Kochubiei O, Demydenko G, et al. Oncostatin M, interleukin-6, glucometabolic parameters and lipid profile in hypertensive patients with prediabetes and type 2 diabetes mellitus. Rom J Diabetes Nutr Metab Dis. 2017;24(4):345–354. doi: 10.1515/rjdnmd-2017-0040.
28. Xie J, Zhu S, Dai Q, et al. Oncostatin M was associated with thrombosis in patients with atrial fibrillation. Medicine. 2017;96(18):e6806. doi: 10.1097/MD.0000000000006806
29. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773–789. doi: 10.1038/s41577-018-0066-7
30. Nagata T, Kai H, Shibata R, et al. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(4):588–593. doi: 10.1161/01.ATV.0000060891.31516.24
31. Han H, Dai D, Du R, et al. Oncostatin M promotes infarct repair and improves cardiac function after myocardial infarction. Am J Transl Res. 2021;13(10):11329-11340.
32. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106(18):2351-2357. doi: 10.1161/01.cir.0000036014.90197.fa
33. Marwah SA, Shah H, Chauhan K, et al. Comparison of mass versus activity of creatine kinase MB and its utility in the early diagnosis of re-infarction. Indian J Clin Biochem. 2014;29(2):161-166. doi:10.1007/s12291-013-0329-9
34. Hsu JT, Chung CM, Chu CM, et al. Predictors of left ventricle remodeling: combined plasma B-type natriuretic peptide decreasing ratio and peak creatine kinase-MB. Int J Med Sci. 2017;14(1):75-85. doi: 10.7150/ijms.17145
Copyright (c) 2022 Anna Gusakova
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.